How did competitive dynamics from biosimilars impact the forecast, given it seems higher than consensus?

The forecast is conservative, assuming compounded products remain, all biosimilars (ranibizumab and aflibercept) enter on time with decreased pricing, and other new therapies (TKIs, IL-6s, gene therapy) are approved. It also factors in pressure from the Good Days Foundation. “I believe our forecast is quite conservative in terms of, you know, to your point, in terms of the evolving market dynamics. We also assume that the Good Days Foundation, which had a significant impact on retina practices and patients in the second half of 2025 and ongoing in 2026, we assume that that would still be some pressure in the market.”

How does the lack of funding from the Good Days Foundation impact patient out-of-pocket costs for LYTENAVA, especially for Medicare patients, compared to compounded products?

While a 20% Medicare co-pay would make LYTENAVA more expensive than compounded, this isn't universal across all patient segments (fee-for-service + supplemental, commercial, Medicare Advantage). The company is working to minimize patient out-of-pocket costs and will leverage available mechanisms like foundations if needed. Practices are becoming sophisticated in assessing patient costs. “However, as we look at our target market and we look and consider the fee-for-service plus supplemental Medigap, we look at commercial, and we look at Medicare Advantage, that out of pocket is not universal across all patients in all segments.”

Will U.S. approval accelerate European rollout, and are there opportunities in Asia?

The company is assessing broader regional expansion (LATAM, Asia, MENA) and receiving inbound calls from potential partners, evaluating bridging studies. European expansion will be strategic, focusing on execution in current markets (UK, Netherlands, Switzerland) and seeking partners. Broader European expansion makes more sense with the pre-filled syringe program, expected later. “Yes, we are looking at a broader Europe, but we are going much more strategic and really wanting to make sure, consume quite a bit of time and resources.”

OTLK

Outlook Therapeutics (OTLK) Q3 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q3 FY26)· Health Care· Aug 14, 2026

Source: earnings call transcript

Executive summary

Outlook Therapeutics Q3 FY26 — FDA Approval of LYTENAVA and U.S. Commercial Launch Preparations

Outlook Therapeutics achieved a transformative milestone with the FDA approval of LYTENAVA for wet AMD, positioning the company for a significant U.S. commercial launch. The strategy focuses on leveraging bevacizumab's established use while navigating a competitive market with biosimilars and pricing pressures. The company is building out its commercial infrastructure and securing funding to support a measured, high-quality market entry, with a focus on market access and reimbursement, while also strategically assessing its European expansion.

Highlights

FDA approved LYTENAVA as the only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the U.S.
LYTENAVA has the potential to generate more than $500 million in peak annual sales by 2030 in the U.S.
Secured $55 million in net proceeds from a public offering to support the U.S. commercial launch.
European unit sales increased by 46% in Q3 FY26 compared to Q2 FY26.

Concerns

The U.S. anti-VEGF market is highly competitive, with biosimilars, TKIs, IL-6s, and gene therapies creating pricing pressures.
The lack of full funding from the Good Days Foundation may impact patient out-of-pocket costs for LYTENAVA.
European market faces challenges including pricing spirals, slow adoption, and regulatory requirements favoring compounding in Germany.
Commercial launch requires strong execution, expanding payer partnerships, appropriate access and reimbursement, and reliable supply.

Guidance & targets

Category	Target	Timeline	Confidence
Total Net Revenue (first 12 months post-U.S. launch)	$50M-$75M high materiality	First 12 months post-U.S. launch · FY27	High
U.S. Launch Revenue Ramp (first 3 months)	~10% of first-year net revenues medium materiality	First 3 months post-U.S. launch · FY27	High
U.S. Launch Revenue Ramp (fourth quarter post-launch)	~50% of first-year net revenues medium materiality	Fourth quarter post-U.S. launch · FY27	High
Quarterly SG&A Expenses	Approximately double from current levels medium materiality	By end of CY26 · FY27	High
Quarterly SG&A Expenses	Additional increase of approximately 10% medium materiality	During CY27 · FY27	High
R&D Expenses	Relatively steady low materiality	Next 12 months · FY27	High
LYTENAVA Peak Annual Sales (U.S.)	>$500M high materiality	By 2030 · FY30	High
Permanent J-code Receipt	April next year high materiality	April 2027 · FY27	High
LYTENAVA WAC Price	Below $500 high materiality	Prior to launch · FY26	High
LYTENAVA Market Share (wet AMD)	30%-35% medium materiality	By 2030 · FY30	High
HCPCS Code Application Submission	Submission completed medium materiality	Q3 · FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Europe European revenue is improving, with unit sales showing significant quarter-over-quarter growth despite a summer slowdown. The company is right-sizing the team and focusing on strategic expansion due to pricing pressures and regulatory complexities in certain markets like Germany. Unit sales growth: 46% QoQ	—	—	—	—

Product announcements

Product	Type	Timeline	Details
LYTENAVA	launch	Late July 2026

Risks & headwinds

Competitive market dynamics Ongoing

Ongoing decreased pricing pressures for all biosimilars, with new entrants like TKIs, IL-6s, and gene therapies.

Mitigation:Focused commercial model, differentiated proposition as the only FDA-approved ophthalmic bevacizumab, and strategic market analysis.

Patient affordability and out-of-pocket costs Ongoing

Impact from changes in funding availability from the Good Days Foundation, potentially increasing patient out-of-pocket costs.

Mitigation:Thoughtful pricing strategy (below $500/vial), leveraging mechanisms to minimize patient burden, and deploying field reimbursement personnel to assist practices.

European market challenges Ongoing

Pricing spiral and intense downward pricing pressure leading some biosimilar companies to not commercialize. Regulatory requirements in Germany favor compounding, creating headwinds.

Mitigation:Right-sizing the European team, strategic market entry, focusing on execution in current markets, and seeking partners for broader expansion.

Regulatory and reimbursement hurdles for U.S. launch Near-term (Q3 FY26 to April 2027)

Need for a permanent HCPCS code (by end of Q3 FY26) and a permanent J-code (by April 2027) to ensure broad market access and reimbursement clarity.

Mitigation:Advancing payer engagement and preparing for timely HCPCS and J-code submissions.

What to watch in Q4 FY26

Permanent J-code Receipt

April next year (April 2027)

Current Anticipated

Target Receipt of J-code

Why it matters

Crucial for broader adoption and commercial growth, especially for Medicare Advantage plans, and expected to accelerate revenue ramp.

We anticipate a progressive launch ramp with approximately 10% of first-year net revenues generated during the first three months, moving up to approximately 50% generated during the fourth quarter following launch. We believe the acceleration in the second half of calendar year 2027 corresponds with the permanent J-code we anticipate receiving in April of next year.

Find out whether OTLK delivers this. Inve re-checks your case every morning.

Q&A highlights

What is the potential upside if repackaged bevacizumab market is disrupted? How many early adopters have been identified and what share of current repackaged use do they represent?

Management estimates a just under $300 million upside if the compounded market is disrupted. Approximately one-third of retina physicians (under 800) represent nearly 50% of the $500M target, primarily using compounded bevacizumab due to payer step-edits, and are potential early adopters. LYTENAVA aims for 30-35% share of the 2.2 million wet AMD repackaged injections by 2030.

“Roughly, if there's any disruption in the compounded repackaged bevacizumab or any significant change in its availability, roughly just under a $300 million upside into that in terms of what can potentially happen.”

asked by Julian Harrison · answered by Robert Jahr

2 min read 6 chapters

Detailed narrative

FDA Approval and Market Opportunity

Outlook Therapeutics recently secured FDA approval for LYTENAVA, an ophthalmic formulation of bevacizumab for wet AMD, marking a significant transformation for the company. This approval addresses a long-standing need for an FDA-approved version of bevacizumab, a molecule widely used off-label for over two decades.

The U.S. anti-VEGF retina market is estimated at $8.5 billion annually, with 3.6 million injections of off-label repackaged bevacizumab in 2025, including 2.2 million for wet AMD. LYTENAVA is positioned as a differentiated option, not competing with branded biosimilars but with the established use of repackaged bevacizumab.

U.S. Commercial Strategy

The company's immediate priority is building the commercial infrastructure for a successful U.S. launch. The retina market's high concentration allows for a focused commercial model, targeting practices currently dissatisfied with compounded bevacizumab and those with high utilization. The strategy emphasizes market access and reimbursement, with plans to submit an application for a permanent HCPCS code by end of Q3 FY26 and anticipate a permanent J-code in April 2027.

Commercial supply is secured for launch later this year, with scaling processes underway.

Pricing and Affordability

Outlook Therapeutics has adopted a thoughtful, research-driven approach to pricing, aiming to support broad access while balancing stakeholder needs. The WAC price for LYTENAVA is expected to be below $500 per vial, competitive with biosimilars while reflecting its differentiated profile. Patient affordability, out-of-pocket costs, and operational realities for buy-and-bill practices have been key considerations, with the company committed to minimizing patient burden.

Commercial and Medical Affairs Build-out

The company is building a specialized commercial organization for the retina market, planning to hire approximately 30 customer-facing commercial personnel and 20 field reimbursement personnel. This structure is designed to support physician engagement, education, and navigation of access/reimbursement processes. The medical affairs organization is also expanding to lead scientific exchange, respond to medical information, and support evidence generation, with a focus on real-world data.

European Market and Global Expansion

In Europe, the company is focused on execution in existing markets like the UK and preparing for launch in the Netherlands in early 2027, which will serve as a regional distribution hub. Strategic expansion into Switzerland in 2027 is also planned.

The company is assessing broader global opportunities in LATAM, Asia, and MENA, seeking partners and evaluating additional bridging studies, with a long-term view that the U.S. will remain the primary commercial opportunity.

Financial Performance and Capital Raise

For Q3 FY26, Outlook Therapeutics reported an adjusted net loss of $10.9 million, or $0.09 per share, an improvement from $15.8 million, or $0.44 per share, in Q3 FY25. Cash and cash equivalents stood at $11.2 million as of June 30th.

Subsequent to quarter-end, the company announced a $55 million public offering, expected to yield approximately $51.1 million in net proceeds, earmarked for the U.S. commercial launch and general corporate purposes.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.